Table 2. Meta-analysis of the p53 codon 72 Arg>Pro polymorphism on hematological malignancy risk.
| Variables | na | Arg/Pro vs. Arg/Arg | Pro/Pro vs. Arg/Arg | Arg/Pro + Pro/Pro vs. Arg/Arg (dominant) | Pro/Pro vs. Arg/Arg + Arg/Pro (recessive) | ||||
| OR (95% CI) | P b | OR (95% CI) | P b | OR (95% CI) | P b | OR (95% CI) | P b | ||
| Total | 13 | 1.08(0.95–1.24) | 0.199 | 1.10(0.83–1.45) | 0.004 | 1.08(0.93–1.26) | 0.033 | 1.05(0.83–1.33) | 0.026 |
| Types | |||||||||
| Leukemia | 9 | 1.03(0.83–1.27) | 0.100 | 1.10(0.71–1.72) | 0.001 | 1.04(0.81–1.34) | 0.010 | 1.07(0.75–1.53) | 0.010 |
| Lymphoma | 3 | 1.18(1.02–1.35) | 0.797 | 1.12(0.80–1.55) | 0.257 | 1.18(1.03–1.34) | 0.719 | 1.02(0.74–1.40) | 0.249 |
| Myeloma | 1 | ||||||||
| Ethnicities | |||||||||
| Asian | 7 | 1.11(0.92–1.34) | 0.235 | 0.99(0.73–1.33) | 0.122 | 1.07(0.86–1.33) | 0.106 | 1.00(0.83–1.21) | 0.389 |
| European | 6 | 1.05(0.85–1.29) | 0.190 | 1.32 (0.74–2.35) | 0.003 | 1.09(0.85–1.40) | 0.037 | 1.31(0.79–2.17) | 0.010 |
| Source of controls | |||||||||
| Hospital based | 5 | 1.00(0.84–1.18) | 0.099 | 0.98(0.73–1.33) | 0.048 | 0.99(0.82–1.19) | 0.027 | 1.00(0.80–1.26) | 0.209 |
| Population based | 8 | 1.02(0.84–1.25) | 0.069 | 1.12(0.73–1.72) | 0.001 | 1.04(0.82–1.31) | 0.006 | 1.11(0.78–1.58) | 0.007 |
a
Number of comparisons.
b
P value of Q-test for heterogeneity test.